FindTrial
Sign In

Survey of Hepatitis C virus infection in Punjab

A population-based survey of the prevalence of hepatitis C virus infection in Punjab, North India

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2013/08/003910
Enrollment
5500
Registered
2013-08-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

MSD Pharmaceuticals Private Limited A subsidiary of Merck Co Inc
Lead Sponsor
MSD Pharmaceuticals Private Limited A subsidiary of Merck Co Inc
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Household members greater than five years of age who have provided voluntary informed consent for participation (For adults aged more than 18 years informed consent will be taken. For children aged more than 5 years and less than 18 years, assent along with informed consent by parents or legally acceptable representative [LAR] will be taken).

Exclusion criteria

Exclusion criteria: Children aged less than 5 years

Design outcomes

Primary

MeasureTime frame
The primary outcome of this survey is the prevalence of HCV infection in general population of Punjab. The primary outcome analyzed for HCV infection will be derived from the results of markers of HCV infection, anti-HCV (screening assay) and HCV RNA.Timepoint: Twelve months—

Secondary

MeasureTime frame
To identify the risk factors for HCV infection in Punjab To assess the prevalence of other hepatotropic viruses in PunjabTimepoint: Twelve months—

Countries

India

Contacts

Public ContactDr Vijay Surlikar

MSD pharmaceuticals

vijay.surlikar@merck.com022-67898888

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026